High levels of circulating interleukin-10 in diabetic nephropathy patients

European Cytokine Network

Volumn 16, Issue 2, 2005, Pages 117-122

  Myśliwska, Jolanta ^a   Zorena, K ^a   Semetkowska Jurkiewicz, E ^a   Rachon D ^a   Suchanek, H ^a   Mysliwski A ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Interleukin 10; Nephropathy; Type 1 diabetes mellitus

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 10;

ADULT; ALBUMINURIA; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KETONURIA; MALE; BLOOD; CASE CONTROL STUDY;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-10; MALE;

EID: 30444449160     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Eibl N, Spatz M, Fischer GF, et al. Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study. Clin Immunol 2002; 103: 249.
2. Chen MK, Wen YS, Chang CC, Lee HS, Huang MT, Hsiao HC. Deep neck infections in diabetic patients. Am J Otolaryngol 2000; 21: 169.
3. Moreno R, Zamorano J, Almeria C, et al. Influence of diabetes mellitus on short- and long-term outcome in patients with active infective endocarditis. J Heart Valve 2002; 11: 651.
4. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17: 1684.
5. Dokter WH, Koopmans SB, Vellenga E. Effects of IL-10 and IL-4 on LPS-induced transcription factors (AP-1, NF-IL-6, NFκB) which are involved in IL-6 regulation. Leukemia 1996; 10: 1308.
6. Korholz D, Banning U, Bonig H, et al. The role of Interleukin-10 in IL-15-mediated T cell responses. Blood 1997; 90: 4513.
7. Lowe PR, Galley HF, Abdel-Fattah A, Webster NR. Influence of Interleukin-10 polymorphism on Interleukin-10 expression and survival in critically ill patients. Crit Care Med 2003; 31: 34.
8. Yeh FL, Shen HD, Fang RH. Deficient transforming growth factor β and interleukin-10 responses contribute to the septic death of burned patients. Burns 2002; 28: 631.
9. Hirayama K, Ebihara I, Yamamoto S, et al. Predominance of Type-2 immune response in idiopathic membranous nephropathy. Nephron 2002; 91: 255.
10. De Fijter JW, Daha MR, Schroeijrs WE, Van Es LA, Van Kooten C. Increased IL-10 production by stimulated whole blood cultures in primary IgA nephropathy. Clin Exp Immunol 1998; 111: 429.
11. Lin CY, Lin CC, Chang GJ, King CC. Defect of cell-mediated immune response against hepatitis B virus: An indication for pathogenesis of hepatitis-B-virus-associated membranous nephropathy. Nephron 1997; 76: 176.
12. Lim CS, Zheng S, Kim YS, et al. TH1/TH2 predominance and proinflammatory cytokines determine the clinicopathological severity of IgA nephropathy. Nephrol Dial Transplant 2001; 16: 269.
13. Huang XR, Kitching AR, Tipping PG, Holdsworth SR. Interleukin-10 inhibits macrophage-induced glomerular injury. J Am Soc Nephrol 2000; 11: 262.
14. Kitching AR, Katerelos M, Mugde SJ, Tipping PG, Power DA, Holds worth SR. Interleukin-10 inhibits experimental mesangial proliferative glomerulonephritis. Clin Exp Immunol 2002; 128: 36.
15. Choi YK, Kim YJ, Park HS, et al. Suppression of glomerulosclerosis by adenovirus-mediated IL-10 expression in the kidney. Gene Ther 2003; 10: 559.
16. Yoshizawa Y, Nomaguchi H, Izaki S, Kitamura K. Serum cytokine levels in atopic dermatitis. Clin Exp Dermatol 2002; 7: 225.
17. Shahin AA, Shaker OG, Hafez N, et al. Circulating Interleukin-6, soluble Interleukin-2 receptors, tumor necrosis factor α, and Interleukin-10 levels in juvenile chronic arthritis: correlations with soft tissue vascularity assessed by power Doppler sonography. Rheumatol Int 2002; 22: 84.
18. Takeoka K, Watanabe M, Matsuzuka F, Miyauchi A, Yoshinori I. Increase of serum Interleukin-10 in intractable Grave's disease. Thyroid 2004; 14: 201.
19. Morin J, Faideau B, Gagnerault MC, Lepault F, Boitard C, Boudaly S. Passive transfer of flt-3L-derived dendritic cells delays diabetes development in NOD mice and associates with early production of interleukin-(IL)-4 and IL-10 in the spleen of recipient mice. Clin Exp Immunol 2003; 134: 388.
20. Goudy KS, Burkhardt BR, Wasserfall C, et al. Systemic overexpression of IL-10 induces CD4 + CD25 + cell populations in vivo and ameliorates type 1 diabetes in non-obese diabetic mice in a dose-dependent fashion. J Immunol 2003; 171: 2270.
21. Szelachowska M, Krȩtowski A, Kinalska I. Decreased in vitro IL-4 and IL-10 production by peripheral blood in first degree relatives at high risk of diabetes Type 1. Horm Metab Res 1998; 30: 526.
22. Kallmann BA, Huther M, Tubes M, et al. Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease. Diabetes 1997; 46: 237.
23. Hanifi-Moghaddam P, Schloot NC, Kappler S, Sei-Bler J, Kolb H. An association of autoantibody status and serum cytokine levels in Type 1 diabetes. Diabetes 2003; 52: 1137.
24. Zerbini G, Bazigalluppi E, Mangili R, Bosi E, Bonifacio E. revalence of GAD65 and IA-2 auto-antibodies in IDDM patients affected by diabetic nephropathy. Diabetologia 1997; 40: 485.
25. Morcos M, Sayed AA, Bierhaus A, et al. Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 2002; 51: 3532.
26. Jones SC, Saunders HJ, Pollock CA. High glucose increases growth and collagen synthesis in cultured human tubulointerstitial cells. Diabetes Med 1999; 16: 932.
27. Wang A, Hascall VC. Hyaluronan structures synthesized by rat mesangial cells in response to hyperglycemia induce monocyte adhesion. J Biol Chem 2003; 279: 10279.
28. Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH. Diabetic nephropathy is associated with low-grade inflammation in Type diabetic patients. Diabetologia 2003; 46: 1402.
29. von Schnakenburg C, Strehlau J, Ehrich JH, Melk A. uantitative gene expression of TGF-β, IL-10, TNF-α and Fas ligand in renal cortex and medulla. Nephrol Dial Transplant 2002; 17: 573.
30. Niemir ZI, Ondracek M, Dworacki G, et al. In situ upregulation of IL-10 reflects the activity of human glomerulonephritides. Am J Kidney Dis 1998; 32: 80.
31. Rangan GK, Wang Y, Harris DCH. Pharmacologic modulators of nitric oxide exacerbate tubulointerstitial inflammation in proteinuric rats. J Am Soc Nephrol 2001; 12: 1696.
32. Maeda H, Kuwahara H, Ichimura Y, Ohtsuki M, Kurakata S, Shiraishi A. TGF-beta enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. J Immunol 1995; 155: 4926.
33. Cottrez F, Groux H. Regulation of TGF-beta response during T cell activation is modulated by IL-10. J Immunol 2001; 167: 773.
34. Chen S, Hong SW, Iglesias-de la Cruz MC, Isono M, Casaretto A, Ziyadeh FN. The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy. Ren Fail 2001; 23: 471.
35. Goumenos DS, Tsakas S, El Nahas AM, et al. Transforming growth factor-beta (1) in the kidney and urine of patients with glomerular disease and proteinuria. Nephrol Dial Transplant 2002; 17: 2145.